Stock Price & Analysis

The S1 support level for ORIC Stock is $7.37 ,The R1 resistant level for ORIC Stock is $9.07.

As of the end of day on 2025-03-06, the price of ORIC Stock was $7.945.

The target price for ORIC Stock according to analyst rating is 18.00, with the highest price target at 21.00 and the lowest at 13.00. Analysts have a Strong Buy rating on ORIC Stock overall.

The market cap of ORIC is $564.7M.

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. The Company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations, and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

ORIC has a total of 100 employees.